| |
September 26, 2023 | 1:00 PM ET Planning to commercialize a gene therapy product? Learn how you can maximize revenue potential and navigate the market’s unique challenges with Trinity Life Sciences. Ready to tackle the elephant? Register Now.
|
|
Today’s Big NewsAug 30, 2023 |
|
Understand how to navigate EU regulations to launch rare disease medicines in European markets. Download guide.
|
|
|
Thank you to Bridge Bank for sponsoring our editorial feature: Fierce 15 |
|
| By Nick Paul Taylor Novo Nordisk is continuing to seek out obesity assets, paying 15 million euros ($16 million) to snap up Embark Biotech in its second weight loss takeover in quick succession. |
|
|
|
By Nick Paul Taylor FibroGen’s rotten run continues. The biotech reported its fourth phase 3 failure in as many months after the market closed Tuesday, flunking a second Duchenne muscular dystrophy trial in quick succession to send it deeper into the mire. |
By Gabrielle Masson Notch Therapeutics is shuttering one of its three cell therapy centers—which also serves as its headquarters—and is working to find positions for its displaced staff at other companies in the industry. |
Sponsored by Novartis Global Biotech Cooperations With the rapid increase in cell and gene manufacturing, companies need support from experienced, reliable, and global, CDMO's with a deep and rich technology network. |
By Max Bayer Scientists at the University of Oxford are once again teaming up CEPI to develop new prototype vaccines aimed at preventing future pandemics. The Norwegian preparers have committed $80 million toward the initiative, which will build on Oxford's adenovirus vaccine platform. |
Sponsored by IPM.ai Using artificial intelligence to predict and uncover de-identified rare disease patients shortens the time to diagnosis, benefiting both patients and life science companies. |
By James Waldron For a few years, it seemed that AgeX Therapeutics was locked in limbo—forever warning its cash was about to run out while never posting developments to its preclinical pipeline. Now, Serina Therapeutics has finally decided to act on the opportunity to leverage AgeX’s public listing as it pushes ahead with its lead Parkinson’s disease therapy. |
By Gabrielle Masson,Max Bayer,Annalee Armstrong Alongside the new year, we've launched a new Fierce Biotech Fundraising Tracker to keep the pulse on the industry's financing. |
By Noah Tong Critics of President Joe Biden's policies to rein in prices for 10 Medicare Part D drugs believe the policy is "draconian" and will stunt innovation in biotech and pharma startups. |
By Conor Hale Abbott aims to build optical coherence tomography into a preferred tool for guiding the placement of stents that increase blood flow to the heart muscle. But a pair of major late-breaking studies comparing OCT to other imaging techniques have delivered mixed results. |
By Kevin Dunleavy Last month, during a quarterly conference call—as Johnson & Johnson considered its future beyond separation of its consumer health unit—Chief Financial Officer Joe Wolk described the company’s appetite for M&A as “voracious." Helping fuel that appetite are the proceeds gained from the spinout of Kenvue. Wednesday, J&J said the offering had generated $13.2 billion in cash. |
By Andrea Park Lucid Hearing unveiled the “highest premium option” in its OTC line of hearing aids this week: The earbud-like $1,300 Tala. |
By Annie Burky In order to address deteriorating adolescent mental health, interventional behavioral health app BeMe Health moved to meet teens where they’re at—online. Amd according to new research, this methodology is proving successful. |
Fierce podcastsDon’t miss an episode |
| This week on "The Top Line," we discuss the trends seen at Cannes Lions, the top compensated CEOs in the industry, and the cancer drug shortage |
|
|---|
|
|
| WhitepaperLearn how process liquids and buffers impact your total cost of ownership (TCO) and how outsourcing can revolutionize your approach, ensuring quality standards and improving productivity. Sponsored by: Thermo Fisher Scientific Process Liquid Preparation Services |
| WhitepaperIn oncology, traditional methods for determining sales force size & structure are no longer appropriate. This paper describes the multiple drivers of sales strategy in oncology markets today. Sponsored by: Blue Matter, strategic consultants in the life sciences |
| ResearchLearn how the right chemical inventory strategy helped save a mid-size CDMO millions of dollars while securing a stable supply of products with just-in-time delivery. Sponsored by: Thermo Fisher Scientific Production Chemicals and Services |
| WebinarDownload this webinar to learn how to avoid pitfalls when characterizing CAR-T cells in your development workflow, how to save time by using one antibody to examine your entire panel of CARs, and more. Sponsored by: Cell Signaling Technology |
| |
|
